| Data | Hora | Fonte | Título | Código | Companhia |
| 14/02/2018 | 20:54 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 21/12/2017 | 19:26 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 21/12/2017 | 09:04 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 14/12/2017 | 09:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 13/12/2017 | 20:00 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 11/12/2017 | 13:26 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 11/12/2017 | 13:22 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 11/12/2017 | 12:55 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 11/12/2017 | 12:37 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 11/12/2017 | 12:27 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 11/12/2017 | 11:52 | Edgar (US Regulatory) | (25-NSE) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 14/11/2017 | 20:23 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 13/11/2017 | 19:13 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 09/11/2017 | 19:25 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 09/11/2017 | 19:11 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 02/11/2017 | 22:06 | PR Newswire (US) | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Ocera Therapeutics, Inc. - OCRX | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 02/11/2017 | 18:40 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 02/11/2017 | 09:14 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 02/11/2017 | 08:56 | GlobeNewswire Inc. | Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encep... | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 02/11/2017 | 08:45 | PR Newswire (US) | Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encep... | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 20/10/2017 | 09:30 | GlobeNewswire Inc. | Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting® | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 23/08/2017 | 10:05 | GlobeNewswire Inc. | Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017 | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 01/08/2017 | 17:05 | GlobeNewswire Inc. | Ocera Therapeutics Reports Second Quarter 2017 Financial Results | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 01/06/2017 | 10:05 | GlobeNewswire Inc. | Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 26/05/2017 | 10:05 | GlobeNewswire Inc. | Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease on Friday, ... | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 09/05/2017 | 17:05 | GlobeNewswire Inc. | Ocera Therapeutics Reports First Quarter 2017 Financial Results and Provides Clinical Update | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 03/05/2017 | 17:05 | GlobeNewswire Inc. | Ocera Therapeutics to Report First Quarter 2017 Financial Results and Provide Clinical Update on May 9, 2017 | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 26/04/2017 | 07:03 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 25/04/2017 | 17:45 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |
| 17/04/2017 | 14:54 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:OCRX | Ocera Therapeutics, Inc. (MM) |